RingCentral Inc. Class A Common Stock vs BIO-TECHNE Corp — how do they compare? RingCentral Inc. Class A Common Stock trades at $78.59 (market cap $6.39B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays the higher dividend (0.44%). Which is the better fit depends on your goals — on Pluang, investors hold RingCentral Inc. Class A Common Stock for 0 Days and BIO-TECHNE Corp for 63 Days on average.
| RNG | TECH | |
|---|---|---|
Market Cap | $6.39B | $11.37B |
Volume | 1,087,767 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $79.82 | $72.61 |
52-Week Low | $24.82 | $43.31 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $7.44B | $11.40B |
Dividend Yield | 0.36% | 0.44% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
RingCentral provides cloud-based business communications and contact center solutions. Its platform combines phone, messaging, video meetings, and customer-service tools.
Read more on RNG →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →